Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1 Gastrointestinal 1

Conditions

Neoplasms 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Bevacizumab 27 Leucovorin 23 Fluorouracil 22 Oxaliplatin 17 Irinotecan 15 Cetuximab 14 pembrolizumab 11 IFL protocol 11 Panitumumab 10 Folfox protocol 10 Capecitabine 10 Gemcitabine 7 adagrasib 5 Cisplatin 5 Carboplatin 5 Ramucirumab 4 Colonoscopy 4 veliparib 3 spartalizumab 3 selpercatinib 3 regorafenib 3 labetuzumab 3 durvalumab 3 conatumumab 3 cemiplimab 3 Pemetrexed 3 Paclitaxel 3 HMPL-013 3 Drug Therapy 3 5,11-methenyltetrahydrohomofolate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Colonic Neoplasms × bexmarilimab × Clear all

NCT05104905 2022-05-11

RENACOL

Faron Pharmaceuticals Ltd

Phase 1/2 Withdrawn

GastrointestinalGenitourinary

Carcinoma, Renal Cell, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡